submit to the journals

Irene Ghobrial

Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, US
Dr Irene Ghobrial is an Associate Professor at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA and an associate member of the Broad Institute, Cambridge, MA. She is the director of the Clinical Investigator Research Programme at the Dana-Farber Cancer Institute, co-director of the Center for Prevention of Progression (CPOP) and co-leader of the Blood Cancer Research Partnership (BCRP). She is also the director of the Michele & Stephen Kirsch Laboratory. She received her medical degree from Cairo University School of Medicine, Egypt. She completed her internal medicine training at Wayne State University, MI, US, and her haematology/oncology subspecialty training at Mayo Clinic College of Medicine, MN, US. Her research focuses on understanding the mechanisms of tumour progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma (MM) and Waldenstrom macroglobulinaemia (WM). She specifically focuses on the role of the malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions that can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored or co-authored more than 250 publications and book chapters, and has received funding support from the National Cancer Institute as well as multiple foundations including Stand Up To Cancer, Leukaemia and Lymphoma Society, Multiple Myeloma Research Foundation and the International Myeloma Foundation. She has received multiple awards including the Ken Anderson Young Investigator Award, Robert A Kyle Award for Research in WM and Mentor of the Year Award at Dana-Farber Cancer Institute.

Authored articles:

European Oncology & Haematology
European Oncology & Haematology. 2018;14(1):18–19 DOI: